Bromide

Bromide

SCHEMBL3939442

Br.COc1cccc(C[Zn])c1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CHRM2 known ✓ P08172 3/20 0.56
CHRM3 known ✓ P20309 2/20 0.56
SIGMAR1 known ✓ Q99720 2/20 0.53
ACHE known ✓ P22303 1/20 0.50
TAAR1 Q96RJ0 3/20 0.60
IDO1 P14902 2/20 0.60
AGXT P21549 2/20 0.60
CHRM1 P11229 2/20 0.56
CMA1 P23946 1/20 0.55
MAOB P27338 2/20 0.53
AOC3 Q16853 1/20 0.53
LPO P22079 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27583382 0.98 TAAR1 (0.62) TAAR1IDO1AGXTCHRM2CHRM1
Hydrochloric Acid SCHEMBL1792281 0.96 IDO1 (0.63) TAAR1IDO1AGXTCHRM2CHRM1
Bromide SCHEMBL28187051 0.83 TAAR1 (0.60) TAAR1IDO1AGXTCHRM2CHRM1
Pivalate SCHEMBL9953510 0.82 CYP1A2 (0.54) CMA1
SCHEMBL723511 0.82 TAAR1 (0.77) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL30080050 0.82 TAAR1 (0.77) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL2099512 0.82 CHRM2 (0.66) TAAR1IDO1AGXTCHRM2CHRM1
Bromide SCHEMBL31513707 0.81 TAAR1 (0.69) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL29908907 0.80 TAAR1 (0.62) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL12497 0.80 TAAR1 (0.62) TAAR1IDO1AGXTCHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2021-03-02 US disclosed
US-10844015-B2 Pyridine dicarboxamide derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2020-11-24 US disclosed
EP-3440069-B1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2020-10-28 EP disclosed
US-20200207741-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE HOFFMANN-LA ROCHE INC. 2020-07-02 US disclosed
US-10640491-B2 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA ROCHE INC. (US) 2020-05-05 US disclosed
US-20190202786-A1 PYRIDINE DICARBOXAMIDE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-07-04 US disclosed
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-04-25 US disclosed
EP-3464242-A1 PYRIDINE DICARBOXAMIDE DERIVATIVES AS BROMODOMAIN INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2019-04-10 EP disclosed
EP-3440069-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) 2019-02-13 EP disclosed
US-20180305340-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE HOFFMANN-LA ROCHE INC. 2018-10-25 US disclosed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 US disclosed
WO-2014078609-A1 PYRROLIDINE GPR40 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-22 WO disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 WO disclosed
EP-2044061-A2 BENZOTHIOPHENE INHIBITORS OF RHO KINASE Kahraman, Mehmet (US) 2009-04-08 EP disclosed
WO-2008011560-A2 BENZOTHIOPHENE INHIBITORS OF RHO KINASE KAHRAMAN MEHMET (US) 2008-01-24 WO disclosed
US-20080009478-A1 Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases ARENA PHARMACEUTICALS, INC. (US) 2008-01-10 US disclosed
WO-2005042491-A1 BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES ARENA PHARMACEUTICALS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180305340-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN CHRM2 4373/4885CHRM3 4325/4885SIGMAR1 3653/4885
US-20080009478-A1 Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases HTR2C, HTR2A, HTR2B CHRM2 631/4885CHRM3 339/4885SIGMAR1 272/4885
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors BRD4, BRD3, BRDT CHRM2 1532/4885CHRM3 982/4885SIGMAR1 3314/4885
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 CHRM2 3092/4885CHRM3 3486/4885SIGMAR1 2418/4885
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT CHRM2 1532/4885CHRM3 982/4885SIGMAR1 3314/4885
US-20200207741-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN CHRM2 4100/4885CHRM3 4142/4885SIGMAR1 3227/4885
US-10640491-B2 Inhibitors of bruton's tyrosine kinase BTK, SYK, LYN CHRM2 4373/4885CHRM3 4325/4885SIGMAR1 3653/4885
US-20190202786-A1 PYRIDINE DICARBOXAMIDE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRPF3 CHRM2 1155/4885CHRM3 702/4885SIGMAR1 3622/4885
US-10844015-B2 Pyridine dicarboxamide derivatives as bromodomain inhibitors BRD4, BRD3, BRPF3 CHRM2 1155/4885CHRM3 702/4885SIGMAR1 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.